{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:07:51Z","timestamp":1791245271255,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-025-08083-7","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:19:45Z","timestamp":1757506785000},"page":"1773-1779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of progestin-only drospirenone-based pills in hyperandrogenic women with polycystic ovary syndrome"],"prefix":"10.1007","volume":"312","author":[{"given":"Alice","family":"Diterlizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Tropea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Notaristefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Moricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Policriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Ranalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasyia","family":"Samasiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Ghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lanzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Apa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"8083_CR1","unstructured":"Teede H et al (2023) International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2023. Monash University. Copyright Monash University, Melbourne, Australia. ISBN: 978-0-6458209-0-4"},{"key":"8083_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.steroids.2003.08.008","volume":"68","author":"W Elger","year":"2003","unstructured":"Elger W, Beier S, Pollow K et al (2003) Conception and pharmacodynamic profile of drospirenone. Steroids 68:891\u2013905","journal-title":"Steroids"},{"issue":"5","key":"8083_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","volume":"92","author":"DF Archer","year":"2015","unstructured":"Archer DF, Ahrendt HJ, Drouin D (2015) Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception 92(5):439\u2013444","journal-title":"Contraception"},{"issue":"12","key":"8083_CR4","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/aogs.13688","volume":"98","author":"S Palacios","year":"2019","unstructured":"Palacios S, Colli E, Regidor PA (2019) Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand 98(12):1549\u20131557","journal-title":"Acta Obstet Gynecol Scand"},{"key":"8083_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.conx.2020.100020","volume":"2","author":"T Kimble","year":"2020","unstructured":"Kimble T, Burke AE, Barnhart KT et al (2020) A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24\/4-day regimen. Contraception X 2:100020","journal-title":"Contraception X"},{"issue":"6","key":"8083_CR6","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s00404-019-05340-4","volume":"300","author":"S Palacios","year":"2019","unstructured":"Palacios S, Colli E, Regidor PA (2019) A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. Arch Gynecol Obstet 300(6):1805\u20131812","journal-title":"Arch Gynecol Obstet"},{"key":"8083_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.contraception.2020.02.004","volume":"101","author":"D Apter","year":"2020","unstructured":"Apter D, Colli E, GemzellDanielsson K, Peters K (2020) Multicenter, open-label trial to assess the safety and tolerability of drospirenone 4.0 mg over 6 cycles in female adolescents, with a 7-cycle extension phase. Contraception 101(6):412\u2013419","journal-title":"Contraception"},{"issue":"6","key":"8083_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2310\/7750.2007.00037","volume":"11","author":"JK Tan","year":"2007","unstructured":"Tan JK, Tang J, Fung K, Gupta AK, Thomas DR, Sapra S, Lynde C, Poulin Y, Gulliver W, Sebaldt RJ (2007) Development and validation of a comprehensive acne severity scale. J Cutan Med Surg 11(6):211\u2013216. https:\/\/doi.org\/10.2310\/7750.2007.00037 (PMID: 18042334)","journal-title":"J Cutan Med Surg"},{"key":"8083_CR9","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1210\/jcem-21-11-1440","volume":"21","author":"D Ferriman","year":"1961","unstructured":"Ferriman D, Gallwey JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440\u20131447. https:\/\/doi.org\/10.1210\/jcem-21-11-1440","journal-title":"J Clin Endocrinol Metab"},{"key":"8083_CR10","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0084-3741(10)79621-9","volume":"10","author":"AW Meikle","year":"2011","unstructured":"Meikle AW (2011) The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Yearb Endocrinol 10:283\u2013284","journal-title":"Yearb Endocrinol"},{"issue":"1","key":"8083_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0010-7824(00)00133-5","volume":"62","author":"R Krattenmacher","year":"2000","unstructured":"Krattenmacher R (2000) Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62(1):29\u201338","journal-title":"Contraception"},{"key":"8083_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.coemr.2020.02.015","volume":"12","author":"E Carmina","year":"2020","unstructured":"Carmina E (2020) Cutaneous manifestations of polycystic ovary syndrome. Curr Opin Endocrinol Metab Res 12:49\u201352","journal-title":"Curr Opin Endocrinol Metab Res"},{"issue":"5","key":"8083_CR13","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/j.0022-202X.2005.23705.x","volume":"124","author":"I Nagy","year":"2005","unstructured":"Nagy I, Pivarcsi A, Koreck A et al (2005) Distinct strains of Propionibacterium acnes induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Investig Dermatol 124(5):931\u2013938. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23705.x","journal-title":"J Investig Dermatol"},{"issue":"1","key":"8083_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/jocd.12543","volume":"18","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Lee SB, Lee HB (2019) Oleic acid enhances keratinocytes differentiation via the upregulation of miR-203 in human epidermal keratinocytes. J Cosmet Dermatol 18(1):383\u2013389. https:\/\/doi.org\/10.1111\/jocd.12543","journal-title":"J Cosmet Dermatol"},{"key":"8083_CR15","doi-asserted-by":"publisher","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, Bowe WP, Graber EM, Harper JC, Kang S, Keri JE, Leyden JJ, Reynolds RV, Silverberg NB, Stein Gold LF, Tollefson MM, Weiss JS, Dolan NC, Sagan AA, Stern M, Boyer KM, Bhushan R (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74(5):945.e33\u2013973.e33. https:\/\/doi.org\/10.1016\/j.jaad.2015.12.037 [Epub 2016 Feb 17] (Erratum in: J Am Acad Dermatol. 2020 Jun;82(6):1576)","DOI":"10.1016\/j.jaad.2015.12.037"},{"issue":"4","key":"8083_CR16","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","volume":"112","author":"JM Maloney","year":"2008","unstructured":"Maloney JM, Dietze P Jr, Watson D, Niknian M, Lee-Rugh S, Sampson-Landers C, Korner P (2008) Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial. Obstet Gynecol 112(4):773\u2013781. https:\/\/doi.org\/10.1097\/AOG.0b013e318187e1c5 (PMID: 18827119)","journal-title":"Obstet Gynecol"},{"issue":"6","key":"8083_CR17","first-page":"633","volume":"12","author":"MB Palli","year":"2013","unstructured":"Palli MB, Reyes-Habito CM, Lima XT, Kimball AB (2013) A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone\/0.02 mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. J Drugs Dermatol 12(6):633\u2013637 (PMID: 23839178)","journal-title":"J Drugs Dermatol"},{"key":"8083_CR18","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/BF03346756","volume":"36","author":"D Romualdi","year":"2013","unstructured":"Romualdi D, De Cicco S, Busacca M, Gagliano D, Lanzone A, Guido M (2013) Clinical efficacy and metabolic impact of two different dosages of ethinyl-estradiol in association with drospirenone in normal-weight women with polycystic ovary syndrome: a randomized study. J Endocrinol Investig 36(8):636\u2013641","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"8083_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","volume":"103","author":"C Klipping","year":"2021","unstructured":"Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM (2021) Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception 103(4):213\u2013221","journal-title":"Contraception"},{"issue":"4","key":"8083_CR20","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.steroids.2011.12.003","volume":"77","author":"F Gonz\u00e1lez","year":"2012","unstructured":"Gonz\u00e1lez F (2012) Inflammation in polycystic ovary syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77(4):300\u2013305. https:\/\/doi.org\/10.1016\/j.steroids.2011.12.003 (Epub 2011 Dec 8)","journal-title":"Steroids"},{"key":"8083_CR21","doi-asserted-by":"crossref","unstructured":"Escobar-Morreale HF, Luque-Ram\u00edrez M, Gonz\u00e1lez F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011 Mar 1;95(3):1048-58.e1-2. doi: 10.1016\/j.fertnstert.2010.11.036. Epub 2010 Dec 17. PMID: 21168133; PMCID: PMC3079565.","DOI":"10.1016\/j.fertnstert.2010.11.036"},{"issue":"4","key":"8083_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.contraception.2003.11.003","volume":"69","author":"U Gaspard","year":"2004","unstructured":"Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R (2004) A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 69(4):271\u2013278","journal-title":"Contraception"},{"issue":"4","key":"8083_CR23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/09513590.2022.2046729","volume":"38","author":"P-A Regidor","year":"2022","unstructured":"Regidor P-A, Palacios S, Colli E (2022) Bleeding profile of women with cardiovascular risk factors using a drospirenone only pill with 4 mg over nine cycles compared to desogestrel 0.075 mg. Gynecol Endocrinol 38(4):333\u2013338","journal-title":"Gynecol Endocrinol"},{"issue":"6","key":"8083_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1080\/13625187.2021.1957094","volume":"26","author":"S Palacios","year":"2021","unstructured":"Palacios S, Colli E, Regidor PA (2021) Metabolic and laboratory effects of a progestin-only pill containing drospirenone 4 mg in comparison to desogestrel 75 \u00b5g: a double-blind, double-dummy, prospective, randomised study. Eur J Contracept Reprod Health Care 26(6):454\u2013461","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"7","key":"8083_CR25","first-page":"2987","volume":"27","author":"S Palacios","year":"2023","unstructured":"Palacios S, Colli E, de Diego MV, Regidor PA (2023) 10-month retrospective study on compliance and tolerability of the drospirenone-only pill. Eur Rev Med Pharmacol Sci 27(7):2987\u20132993","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"7","key":"8083_CR26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/17512433.2020.1783247","volume":"13","author":"MCD Savio","year":"2020","unstructured":"Savio MCD, De Fata R, Facchinetti F, Grandi G (2020) Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception. Expert Rev Clin Pharmacol 13(7):685\u2013694. https:\/\/doi.org\/10.1080\/17512433.2020.1783247","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"8083_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/13625189809167250","volume":"3","author":"T Korver","year":"1998","unstructured":"Korver T (1998) A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 \u03bcg\/day or levonorgestrel 30 \u03bcg\/day: Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur J Contracept Reprod Health Care 3(4):169\u2013178","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"8083_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/13625187.2022.2164186","volume":"28","author":"A Kubba","year":"2023","unstructured":"Kubba A, Gemzell-Danielsson K, Palacios S, Wiegratz I, Grandi G, Colli E, Regidor PA (2023) The drospirenone (DRSP)-only pill: clinical implications in the daily use. Eur J Contracept Reprod Health Care 28(1):36\u201343. https:\/\/doi.org\/10.1080\/13625187.2022.2164186","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"10\u201313","key":"8083_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.steroids.2003.08.008","volume":"68","author":"W Elger","year":"2003","unstructured":"Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A (2003) Conception and pharmacodynamic profile of drospirenone. Steroids 68(10\u201313):891\u2013905. https:\/\/doi.org\/10.1016\/j.steroids.2003.08.008","journal-title":"Steroids"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08083-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-025-08083-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-025-08083-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T07:29:27Z","timestamp":1762327767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-025-08083-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["8083"],"URL":"https:\/\/doi.org\/10.1007\/s00404-025-08083-7","relation":{},"ISSN":["1432-0711"],"issn-type":[{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}